Solventum (FRA:KB7) Current Accrued Expense: €0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:KB7 Solventum Corp FRA:KB7
30 GF Score
Price €75.60
! 8 Warning Signs
View Full Analysis

What is Solventum Current Accrued Expense?

Solventum FRA:KB7 30 Current Accrued Expense is €0 Mil as of Jun. 2026. GuruFocus rates FRA:KB7 with a GF Score™ of 30/100. The stock has 8 warning signs investors should review.

Solventum's Current Accrued Expense for the quarter that ended in Jun. 2026 was €0 Mil.

Solventum's quarterly Current Accrued Expense declined from Dec. 2025 (€208 Mil) to Mar. 2026 (€0 Mil) but then stayed the same from Mar. 2026 (€0 Mil) to Jun. 2026 (€0 Mil).

Solventum's annual Current Accrued Expense increased from Dec. 2023 (€189 Mil) to Dec. 2024 (€248 Mil) but then declined from Dec. 2024 (€248 Mil) to Dec. 2025 (€208 Mil).

Solventum Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Solventum's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solventum Current Accrued Expense Chart

Solventum Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 167.27 158.59 188.90 248.30 207.52

Solventum Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 226.29 180.62 207.52 0.00 0.00
FRA:KB7
30GF Score
Solventum Corp FRA:KB7
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Solventum Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of €0 Mil mean?
Solventum (FRA:KB7) has a Current Accrued Expense of €0 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Solventum and its competitors.
Is Solventum's Current Accrued Expense too high?
Solventum's current Current Accrued Expense is €0 Mil. Overall, Solventum has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Solventum's Current Accrued Expense compare to COO and ALGN?
Solventum's Current Accrued Expense of €0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Medical Devices & Instruments company?
A good Current Accrued Expense depends on the Medical Devices & Instruments industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Solventum and its competitors. Solventum's current Current Accrued Expense is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solventum stock overvalued right now?
Solventum (FRA:KB7) has a current Current Accrued Expense of €0 Mil. The current Current Accrued Expense is €0 Mil. Solventum's overall GF Score™ is 30/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Solventum (FRA:KB7), the current Current Accrued Expense is €0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Solventum Business Description

Address 2510 Conway Avenue East, 3M Center, Building 275-6W, Maplewood, MN, USA, 55144
Solventum Corp is a healthcare company developing, manufacturing, and commercializing solutions leveraging material science, data science, and digital capabilities to address customer and patient needs. Its segments include MedSurg, which earns maximum revenue and provides wound therapy, I.V. site management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and OEM medical technologies; Dental Solutions, offering dental and orthodontic products such as brackets, restorative cements, and bonding agents; and Health Information Systems, providing software solutions including physician documentation, coding automation, speech recognition, and data visualization platforms. It operates in the United States, which earns the majority of revenue, and internationally.
30GF Score

Get the complete analysis for FRA:KB7

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€75.60
Price